Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 4

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 4
---
 Added Strong Analyst Coverage from Well Known Banks average daily trading volume prior to Neil’s tenure1 average daily trading volume today2 424k 99k Improved Trading Liquidity of shares outstanding were held by the top 20 institutional investors prior to Neil’s tenure 55% 10% Attracted Bedrock Biotech Institutional Investors 480 of shares outstanding are held by the top 20 institutional investors as of most recent public filings

October 2023: Appointed Neil McFarlane as President, CEO November 2023: Completed Acquisition of Acer Therapeutics June 2024: Announced Positive Final Results from Phase 2 Clinical Trial of KP1077 Appointed Rahsaan W. Thompson as Chief Legal Officer and Alison Peters as Chief People Officer September 2024: MIPLYFFA FDA Approval and Received Priority Review Voucher (PRV) November 2024: Announced U.S. Commercial Availability of MIPLYFFA Completed Portfolio Assessment and Launched Strategic Plan for 2025 and Five-Year Vision April 2025: Sold PRV for $150M January 2024: Appointed Adrian Quartel as Chief Medical Officer Launched first-ever commercial product OLPRUVA March 2024: Announced Positive Top-Line Data from Phase 2 Clinical Trial of KP1077 and demonstrated clinically meaningful benefits for key IH symptoms Reinitiated Recruitment for phase 3 DiSCOVER trial of celiprolol Neil F. McFarlane Chief Executive Officer and President Rahsaan W. Thompson Chief Legal Officer, Secretary, and Compliance Officer Alison Peters Chief People Officer Our Board and Management Achieved Many Recent Milestones, Driving Stockholder Value A Track Record of Success During Neil McFarlane’s Tenure Adrian Quartel Chief Medical Officer

Analysts are Supportive of our Board, Management Team, and Strategy April 2025 One of the best rare disease executions we’ve seen right off the bat. Based on this early commercial transition, we strongly believe this is a team to get behind and one that is passionately putting patients first. March 2025 We believe the Company’s leadership has significant experience in the rare disease space that will help build it into a successful player in rare disease. “ ” “ ” March 2025 We like what we see so far on ZVRA's ability to carry out its rare disease-focused strategy. Risks to achieving target price: potential distractions caused by any additional management and/or board changes. “ ” November 2024 Before the product is even available, >25% of U.S